Projects per year
Personal profile
Chinese Name
Research Interests
Chinese Medicine, Clinical Pharmacology and Arthritis and related new drug discovery
Biography
Professor Lyu Aiping is Chair Professor & Dean of School of Chinese Medicine, Hong Kong Baptist University, Director of Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer & Inflammation Research (CCIR) of HKBU, member of Academia Europaea, Chair Professor in China Academy of Chinese Medical Sciences (CACMS) and Recipient of the Distinguished Young Scholar in National Science Foundation of China (NSFC) in 2007. Prof. Lyu is also the member of Hong Kong Chinese Medicine Development Committee, the member of Hong Kong Chinese Medicine Administration Committee, the member of Biology and Medicine Panel in Hong Kong Research Grant Committee (RGC).
He obtained his bachelor degree from Jiangxi University of Traditional Chinese Medicine in 1983, and further obtained his master's and Ph.D. degrees from China Academy of Traditional Chinese Medicine (now called the China Academy of Chinese Medical Sciences, CACMS). From 2006 to 2012, he was the Director of Institute of Basic Research in Clinical Medicine, and the Director of Institute of Basic Theory of CACMS from 1999 to 2002. In 2002-2006, Prof Lyu was appointed as General Director, Jiangxi Herbfine Hi-tech Co. Ltd (National Pharmaceutical Engineering Centre), one of four centres in China in the field of Traditional Chinese Medicine industry.
His research interests mainly focus on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with re-classification and interventions, and development of new drugs based on Chinese medicines. Also he is actively involving the research on the standardization of Chinese medicine and strategic plan research for Chinese medicine development in China.
Professor Lyu is a world-leading scientist in aptamer-based translational medicine and drug discovery. He is not only working on basic research that demonstrates novel precision medicine-based therapeutic strategies for rheumatic disease treatment, but also on translational research in collaboration with pharmaceutical industry for the development of novel therapeutic agents. He is the director of the first aptamer R&D platform in Guangdong-Hong Kong-Macao Greater Bay Area of China, which has attracted aptamer pharmaceutical industries to establish "Aptamer Drug Valley" in the Hong Kong Science Park. He has developed the world's first ever osteoblast-targeting nucleic acid aptamer. His first discovery of the therapeutic aptamer targeting Sclerostin loop3 has been granted Orphan Drug Designation by US FDA (DRU-2019-6966) for evaluating the therapeutic potential for promoting bone formation in osteogenesis imperfect. He has also developed the first aptamer-Paclitaxel conjugates, which showcased a precision medicine-based personalized Paclitaxel for targeting specific cancer types, which is currently being developed into anti-cancer therapeutics by a pharmaceutical company.
Professor Lyu initiated the idea of using systems biology approach to identify metabolite biomarkers for subtyping RA patients with distinct clinical manifestations. His clinical research has also underpinned the potent efficacy of Tripterygium wilfordii Hook F. based therapy for RA treatment, which is recommended by the Chinese Association of Integrative Medicine as the Evidence-based Clinical Practice Guidelines. Besides, Professor Lyu has established the China's largest biobank of rheumatic diseases in Shanghai Guanghua Hospital of Integrative Medicine. The biobank has facilitated his discovery of the molecular mechanism addressing the limited efficacy of Leflunomide on bone erosion in a subgroup of RA patients with elevated serum C-reactive protein.
Prof Lyu has more than 600 publications with Google Scholar H index 66, i10-index 370 and a total of over 18000 citations. Over the years, he obtained more than 60 patents from his research activities.
Being a renowned expert and academic in the field, Prof Lyu has been appointed as Head & Spokesperson of the China Delegation, International Organization for Standardization Technical Committee on TCM (ISO/TC249) since 2009. Besides, he also currently serves as Member of Medical Advisory Committee of National Natural Science Foundation of China (NSFC), Member of Chinese Pharmacopoeia Commission and Vice-Chairman, Terminology of Traditional Chinese Medicine Sub-Committee, China National Committee for Terms in Sciences and Technologies (CNCTST). Also he is the director of Chinese Medicine Standardization Office in State Administration of Traditional Chinese Medicine (SATCM), and the director of Chinese Medicine Standard Research Center in CACMS. Most recently, he has been elected Foreign Member of the Academia Europaea.
He was invited to serve as Visiting Scholar in a number of institutions including Lund University in Sweden, Ohio State University in the United States, Hong Kong Polytechnic University and Hong Kong University of Science and Technology. Based on his outstanding research achievement, Prof Lyu was invited as guest speakers in various international academic conferences.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
- 1 Similar Scholars
Collaborations and top research areas from the last five years
-
Construction of a Traditional Chinese Medicine Diagnostic and Treatment Assistance System for Long COVID Based on Big Data and Artificial Intelligence 基於大數據和人工智能的長新冠中醫診療輔助系統搭建
TIAN, L., Zhong, L., TANG, L. H., LYU, A., LIU, J., ZHOU, C. & Lam, P. Y.
1/11/23 → 31/10/25
Project: Research project
-
Construction of a Traditional Chinese Medicine Diagnostic and Treatment Assistance System for Long COVID Based on Big Data and Artificial Intelligence
TIAN, L., Zhong, L., TANG, L. H., LYU, A., LIU, J., ZHOU, C. & Lam, P. Y.
1/11/23 → 31/10/25
Project: Research project
-
A novel TCM-based network pharmacology framework to human diseases and drug-disease relationship
TIAN, L., LYU, A., TANG, L. H., Zhang, Q., Zhong, L., Yang, X. & YANG, Z.
1/06/23 → 31/05/26
Project: Research project
-
Development of combination therapy using a mCRP aptamer and Leflunomide for precision medicine-based rheumatoid arthritis treatment
1/01/23 → …
Project: Research project
-
ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support
Fu, L., Shi, S., Yi, J., Wang, N., He, Y., Wu, Z., Peng, J., Deng, Y., Wang, W., Wu, C., Lyu, A., Zeng, X., Zhao, W., Hou, T. & Cao, D., 5 Jul 2024, In: Nucleic Acids Research. 52, W1, p. W422-W431 10 p.Research output: Contribution to journal › Journal article › peer-review
Open Access35 Citations (Scopus) -
Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release
Ma, Y., Xie, D., Chen, Z., Shen, X., Wu, X., Ding, F., Ding, S., Pan, Y., Li, F., Lu, A. & Zhang, G., 1 Jul 2024, In: Journal of Translational Medicine. 22, 1, 13 p., 604.Research output: Contribution to journal › Journal article › peer-review
Open Access -
A novel network pharmacology strategy to decode mechanism of Wuling Powder in treating liver cirrhosis
Liu, Q., Li, X., Li, Y., Luo, Q., Fan, Q., Lu, A., Guan, D. & Li, J., 1 Mar 2024, In: Chinese Medicine (United Kingdom). 19, 1, 17 p., 36.Research output: Contribution to journal › Journal article › peer-review
Open Access -
Aptamer Functionalized Hypoxia-potentiating Agent and Hypoxia-inducible Factor Inhibitor Combined with Hypoxia-activated Prodrug for Enhanced Tumor Therapy
Ma, Y., Zhang, H., Shen, X., Yang, X., Deng, Y., Tian, Y., Chen, Z., Pan, Y., Luo, H., Zhong, C., Yu, S., Lu, A., Zhang, B., Tang, T. & Zhang, G., 28 Aug 2024, In: Cancer Letters. 598, 12 p., 217102.Research output: Contribution to journal › Journal article › peer-review
Open Access -
Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer
Chen, Y., Yang, J., Wang, C., Wang, T., Zeng, Y., Li, X., Zuo, Y., Chen, H., Zhang, C., Cao, Y., Sun, C., Wang, M., Cao, X., Ge, X., Liu, Y., Zhang, G., Deng, Y., Peng, C., Lu, A. & Lu, J., 25 Jul 2024, In: Journal of Experimental and Clinical Cancer Research. 43, 1, 18 p., 207.Research output: Contribution to journal › Journal article › peer-review
Open Access2 Citations (Scopus)
Prizes
-
1st Prize of China Standard Innovation Contribution Award 2020年中国标准创新贡献奖 - 一等奖
LYU, Aiping (Recipient), 2020
Prize
-
1st Prize of Shanghai Science and Technology Progress Award 上海市科学技术奖 - 一等奖
LYU, Aiping (Recipient), 2020
Prize
-
-
Activities
-
Hong Kong Science and Technology Park (External organisation)
Aiping LYU (Committee/panel/advisory board member)
2023 → 2025Activity: Membership › Membership of board/committee/council
-
RGC-Research Grants Council, HKSAR (External organisation)
Aiping LYU (General member)
2023 → …Activity: Membership › Membership of board/committee/council
-
國家第十二屆藥典委員會 (External organisation)
Aiping LYU (Committee/panel/advisory board member)
2022 → …Activity: Membership › Membership of board/committee/council
-
OTC Naturals Advisory Board (External organisation)
Aiping LYU (President)
2022 → …Activity: Membership › Membership of board/committee/council
-
Academia Europaea (External organisation)
Aiping LYU (General member)
2022 → …Activity: Membership › Membership of board/committee/council
Press/Media
-
From Molecular Target to Aptamer Drug Discovery towards US-FDA Orphan Drug Designation
Yuanyuan YU, Ge ZHANG, Aiping LYU & Luyao WANG
19/12/22 → 20/12/22
4 Media contributions
Press/Media
-
Uncover vast potential of integrative medicine by improving trials, quality control of herbal formulas
5/11/21
1 Media contribution
Press/Media